Pregabalin Zentiva

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalin

Available from:

Zentiva, k.s.

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptics,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Neuropathic pain , Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , Epilepsy , Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , Generalised anxiety disorder , Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.

Product summary:

Revision: 15

Authorization status:

Authorised

Authorization date:

2015-07-17

Patient Information leaflet

                                58
B. PACKAGE LEAFLET
59
PACKAGE LEAFLET: INFORMATION FOR THE USER
PREGABALIN ZENTIVA 25 MG HARD CAPSULES
PREGABALIN ZENTIVA 50 MG HARD CAPSULES
PREGABALIN ZENTIVA 75 MG HARD CAPSULES
PREGABALIN ZENTIVA 100 MG HARD CAPSULES
PREGABALIN ZENTIVA 150 MG HARD CAPSULES
PREGABALIN ZENTIVA 200 MG HARD CAPSULES
PREGABALIN ZENTIVA 225 MG HARD CAPSULES
PREGABALIN ZENTIVA 300 MG HARD CAPSULES
pregabalin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pregabalin Zentiva is and what it is used for
2.
What you need to know before you take Pregabalin Zentiva
3.
How to take Pregabalin Zentiva
4.
Possible side effects
5.
How to store Pregabalin Zentiva
6.
Contents of the pack and other information
1.
WHAT PREGABALIN ZENTIVA IS AND WHAT IT IS USED FOR
Pregabalin Zentiva belongs to a group of medicines used to treat
epilepsy, neuropathic pain
and generalised anxiety disorder (GAD) in adults.
PERIPHERAL AND CENTRAL NEUROPATHIC PAIN
Pregabalin Zentiva is used to treat long lasting pain caused by damage
to the nerves. A variety
of diseases can cause peripheral neuropathic pain, such as diabetes or
shingles. Pain sensations may
be described as hot, burning, throbbing, shooting, stabbing, sharp,
cramping, aching, tingling,
numbness, pins and needles. Peripheral and central neuropathic pain
may also be associated with
mood changes, sleep disturbance, fatigue (tiredness), and can have an
impact on physical and social
functioning and overall quality of life.
EPILEPSY
Pregabalin Zentiva is used to treat a certain form of ep
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Pregabalin Zentiva 25 mg hard capsules
Pregabalin Zentiva 50 mg hard capsules
Pregabalin Zentiva 75 mg hard capsules
Pregabalin Zentiva 100 mg hard capsules
Pregabalin Zentiva 150 mg hard capsules
Pregabalin Zentiva 200 mg hard capsules
Pregabalin Zentiva 225 mg hard capsules
Pregabalin Zentiva 300 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pregabalin Zentiva 25 mg hard capsules
Each hard capsule contains 25 mg of pregabalin.
Excipient with known effect
Each hard capsule also contains 47.57 mg lactose monohydrate.
Pregabalin Zentiva 50 mg hard capsules
Each hard capsule contains 50 mg of pregabalin.
Excipient with known effect
Each hard capsule also contains 5 mg lactose monohydrate.
Pregabalin Zentiva 75 mg hard capsules
Each hard capsule contains 75 mg of pregabalin.
Excipient with known effect
Each hard capsule also contains 7.5 mg lactose monohydrate.
Pregabalin Zentiva 100 mg hard capsules
Each hard capsule contains 100 mg of pregabalin.
Excipient with known effect
Each hard capsule also contains 10 mg lactose monohydrate.
Pregabalin Zentiva 150 mg hard capsules
Each hard capsule contains 150 mg of pregabalin.
Excipient with known effect
Each hard capsule also contains 15 mg lactose monohydrate.
Pregabalin Zentiva 200 mg hard capsules
Each hard capsule contains 200 mg of pregabalin.
Excipient with known effect
Each hard capsule also contains 20 mg lactose monohydrate.
Pregabalin Zentiva 225 mg hard capsules
Each hard capsule contains 225 mg of pregabalin.
3
Excipient with known effect
Each hard capsule also contains 22.5 mg lactose monohydrate.
Pregabalin Zentiva 300 mg hard capsules
Each hard capsule contains 300 mg of pregabalin.
Excipient with known effect
Each hard capsule also contains 30 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsules
Pregabalin Zentiva 25 mg hard capsules
Light grey cap and light grey body; approx. 15,9 mm in length, hard
gela
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-07-2015
Patient Information leaflet Patient Information leaflet Spanish 19-03-2024
Public Assessment Report Public Assessment Report Spanish 27-07-2015
Patient Information leaflet Patient Information leaflet Czech 19-03-2024
Public Assessment Report Public Assessment Report Czech 27-07-2015
Patient Information leaflet Patient Information leaflet Danish 19-03-2024
Public Assessment Report Public Assessment Report Danish 27-07-2015
Patient Information leaflet Patient Information leaflet German 19-03-2024
Public Assessment Report Public Assessment Report German 27-07-2015
Patient Information leaflet Patient Information leaflet Estonian 19-03-2024
Public Assessment Report Public Assessment Report Estonian 27-07-2015
Patient Information leaflet Patient Information leaflet Greek 19-03-2024
Public Assessment Report Public Assessment Report Greek 27-07-2015
Patient Information leaflet Patient Information leaflet French 19-03-2024
Public Assessment Report Public Assessment Report French 27-07-2015
Patient Information leaflet Patient Information leaflet Italian 19-03-2024
Public Assessment Report Public Assessment Report Italian 27-07-2015
Patient Information leaflet Patient Information leaflet Latvian 19-03-2024
Public Assessment Report Public Assessment Report Latvian 27-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 19-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-07-2015
Patient Information leaflet Patient Information leaflet Maltese 19-03-2024
Public Assessment Report Public Assessment Report Maltese 27-07-2015
Patient Information leaflet Patient Information leaflet Dutch 19-03-2024
Public Assessment Report Public Assessment Report Dutch 27-07-2015
Patient Information leaflet Patient Information leaflet Polish 19-03-2024
Public Assessment Report Public Assessment Report Polish 27-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 19-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 19-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-07-2015
Patient Information leaflet Patient Information leaflet Romanian 19-03-2024
Public Assessment Report Public Assessment Report Romanian 27-07-2015
Patient Information leaflet Patient Information leaflet Slovak 19-03-2024
Public Assessment Report Public Assessment Report Slovak 27-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 19-03-2024
Public Assessment Report Public Assessment Report Slovenian 27-07-2015
Patient Information leaflet Patient Information leaflet Finnish 19-03-2024
Public Assessment Report Public Assessment Report Finnish 27-07-2015
Patient Information leaflet Patient Information leaflet Swedish 19-03-2024
Public Assessment Report Public Assessment Report Swedish 27-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 19-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 19-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 19-03-2024
Patient Information leaflet Patient Information leaflet Croatian 19-03-2024
Public Assessment Report Public Assessment Report Croatian 27-07-2015

Search alerts related to this product